Home Search
reverse - search results
If you're not happy with the results, please do another search
Going Public. Direct Listing Update, (Anthony L.G., PLLC)
December 28th, 2021
The rules related to direct listings continue to evolve as this method of going public continues to gain in popularity. The last time I...
Innovus (INNV) Gains 75% in Past Week.
After Rough Sledding Post Reverse Split, Client Innovus Receives Buyout Offer From Nasdaq Listed Ayto Biosciences (AYTU).
Click here to receive post-merger report.
INNOVUS LIVE CHART
TRADING...
Innovus Pharma Reports 2Q 2019 of $6.8 million, a 27.7% Increase from Prior Quarter.
Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB: INNV), an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and...
Internet Stock Review Adds MySize (MYSZ) $0.45 to Watch List.
Short Term Turbulence Creates Potential Entry Point at $0.45.
Investors appeared to react swiftly to an 8K, which looked a lot like they were facing...
Innovus (INNV) Hits the Trifecta. Stuffy Noses, Hair Loss & Heartburn.
Innovative Innovus now has Three Shots on Goal with non-prescription drugs which have come off patent including a new competitor to Prilosec ® ....
Innovus (INNV) in Silicon Review Interview.
POISED FOR INNOVATION.
The Silicon Review is the world’s most trusted online and print community for business & technology professionals. Our community members include thought-provoking...
Innovus (INNV) Conference Call Transcript.
Q1 2019 Results, 5/15/19.
Innovus Pharmaceuticals, Inc. (OTCQB:INNV) Q1 2019 Earnings Conference Call May 15, 2019 4:15 PM ET
Company Participants
Bassam Damaj - President and CEO
Ryan...
Adding Innovus Pharma (INNV) $2.50 to Watch List.
Fast Growing eCommerce and Direct to Consumer Pharma Company Announces 1st Foray into CBD and 2nd Major Off-Patent Blockbuster Drug to its lineup.
We're adding...











